Stock Ratings / Health Care / INFU / earnings

ANIK (55) OSUR (32) TMCI (41) CLPT (34) ⌘ Pro Terminal →

InfuSystems Holdings Inc. (INFU) Next Earnings Date & Expected ±7.8% Move

$14.45 +0.91% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.51

InfuSystems Holdings Inc. (INFU) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate) →

ROARABLE B+ • BUY Cap $287.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.51 (+0.40%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 16.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk A

Each axis scored 0–20

12M PRICE TARGET CONE+8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INFU)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (76/100 Composite)

🔍 WHY INFU SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 5.16 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Macro Regime Fit+18/20 pts (24% of score)

FRED Regime × Technicals: 97% of 52W Range • RSI-14 at 58.6 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$13.56-1.2% Next Q

Q2 (-2Q)

Grade B$13.40+4% Next Q

Q3 (-1Q)

Grade B$13.94+3.7% Next Q

Current

Grade B+$14.45+7.6% Hist 90D α

Trajectory: B- (68) → B+ (76)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INFU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, INFU faces multiple-compression risk if 43.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 53.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.97) or 200D SMA ($10.33) invalidates the momentum regime and cuts Target Base ($15.62) toward Bear Floor ($11.85).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INFU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INFU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 76%NO 24%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±7.8% Swing Band

±$1.13 Expected Swing

MODEL EARNINGS SETUP GAUGE

INFU Quantitative Pre-Earnings Setup: 76/100

Trailing EPS: $0.33 • YoY Revenue Growth: 6.4%

Model Bullish Setup (76/100)Model Risk Weight (24/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$143.4M	$6.6M	$23.8M	56%
FY 2024	2024-12-31	$134.9M	$2.3M	$19.4M	52.2%
FY 2023	2023-12-31	$125.8M	$872.0K	$11.2M	56%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating INFU & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on INFU
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INFU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.65%▲ ASCENDING CHANNEL

2026-10-30O $14.45H $14.59L $13.92C $14.45VOL 130.3K

RES: $15.20SUP: $9.72SMA50: $12.97SMA200: $10.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INFU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INFU Butterfly Map → + Track INFU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

32.6%/yr Implied 5Y Growth

vs. +6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INFU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INFU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INFU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INFU)

Health Care Rank #36 of 1016 ⚔️ ANIK vs INFU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INFU vs. ANIK, OSUR, TMCI, CLPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InfuSystems Holdings Inc. (INFU) ranks #36 by composite RQD confidence (76/100, grade B+) and #525 by equity capitalization ($287.8M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INFU ACTIVE InfuSystems Holdings Inc.	B+	76/100	43.4x	56.0%	12.8%	+0.91%	$287.8M	Benchmark Subject
ANIK Anika Therapeutics Inc.	D+	55/100	—	56.6%	-10.2%	+1.11%	$291.6M	/anik-vs-infu →
OSUR OraSure Technologies Inc.	E	32/100	—	41.9%	-35.0%	-0.49%	$281.4M	/osur-vs-infu →
TMCI Treace Medical Concepts Inc.	D-	41/100	—	79.8%	-32.4%	+4.76%	$329.1M	/tmci-vs-infu →
CLPT ClearPoint Neuro Inc.	E	34/100	—	61.4%	-35.0%	+1.23%	$342.7M	/clpt-vs-infu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001337013

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InfuSystems Holdings Inc. (INFU) reported GAAP revenue of $143.4M (+6.4% vs. FY2024 revenue of $134.9M , and +14.0% cumulative change since FY2023) , GAAP net income of $6.6M, operating cash flow of $24.4M, and free cash flow of $23.8M (+23.1% YoY). On the balance sheet, INFU closed FY2025 with $100.6M in total assets against $19.6M in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$143.4M	$6.6M	$24.4M	$23.8M	$100.6M	$19.6M
FY2024 (FY)	2024-12-31	$134.9M	$2.3M	$20.5M	$19.4M	$103.6M	$23.9M
FY2023 (FY)	2023-12-31	$125.8M	$872.0K	$11.2M	$11.2M	—	—

3. INFU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INFU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InfuSystems Holdings Inc. (NYSE: INFU) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $14.45 (+0.91% 1D, market cap $287.8M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INFU ranks #36 in composite RQD confidence.

How does INFU compare to ANIK and OSUR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), INFU carries a Roarable B+ (76/100 RQD), trailing P/E of 43.4x, gross margin of 56.0%, and ROIC of 12.8%. By comparison, ANIK (Anika Therapeutics Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M) and OSUR (OraSure Technologies Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $281.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INFU?

Per INFU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001337013), InfuSystems Holdings Inc. generated $143.4M in revenue (+6.4% YoY), $6.6M in net income, and $23.8M in free cash flow against $100.6M in total assets and $19.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INFU trading relative to its 50-day, 200-day, and 52-week technical levels?

INFU last traded at $14.45 (+0.91% on volume of 74,910 shares), positioning the stock +11.41% above its 50-day simple moving average ($12.97) and +39.88% above its 200-day simple moving average ($10.33). Across its 52-week range of $7.29 to $14.64, INFU sits at the 97.4% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($13.32 to $15.58).

INFU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is INFU's next earnings date?

Based on SEC filing cadence, InfuSystems Holdings Inc. (INFU)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is INFU stock expected to move on earnings?

Volatility modeling currently projects a ±7.8% event move for INFU, spanning a range between $13.32 and $15.58.

Direct Sub-Reports: INFU RQD Cockpit INFU 12M Forecast INFU Earnings & Move INFU Dividends & DRIP INFU Insiders & 13F INFU Whale Options INFU Profit Sankey INFU News & Why